Oruka Therapeutics, Inc. Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc.

ORKA

Pozycja w akcjach #3292
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Cena akcji
$80.01
Ostatnia synchronizacja: 2026-10-21
Kapitalizacja rynkowa
$5.30B
Zmiana (1 dzień)
1.16%
Zmiana (1 rok)
200.21%
Kraj
US
Handel Oruka Therapeutics, Inc. (ORKA)

Kategoria

Healthcare
Historia ceny akcji dla Oruka Therapeutics, Inc. (ORKA)
Najwyższa cena zamknięcia: $79.07 dnia 2026-10-01

Najniższa cena zamknięcia: $4.84M dnia 1997-12-01
Historia cen akcji firmy Oruka Therapeutics, Inc. od 1997 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2026 (TTM) 94.42%
2025 42.90%
2024 -0.16%
2023 -22.61%
2022 -0.72%
2021 -45.08%
2020 -24.36%
2019 -28.32%
2018 -68.07%
2017 -46.86%
2016 -51.59%
2015 -15.86%
2014 -43.56%
2013 -26.26%
2012 -71.67%
2011 -61.96%
2010 8.83%
2009 -51.11%
2008 -84.91%
2007 -76.28%
2006 3.31%
2005 -17.12%
2004 -4.50%
2003 257.05%
2002 -86.09%
2001 -11.58%
1999 76.44%
1998 -48.78%
1997 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
$527.18 23.62%
US
$251.29 835.90%
US
$137.83 -3.78%
AU
$890.85 9.42%
NL
$757.97 7.73%
CH